Goldman Sachs Group Inc Aligos Therapeutics, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$1.06 - $27.5 $90,010 - $2.34 Million	-84,916 Reduced 85.81%	14,043 $15,000
Q3 2022 Nov 10, 2022	SELL	$1.06 - $27.5 $90,010 - $2.34 Million	-84,916 Reduced 85.81%	14,043 $0
Q2 2022 May 14, 2024	BUY	$1.04 - $2.14 $102,917 - $211,772	98,959 New	98,959 $120,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $2.14 $33,491 - $68,914	-32,203 Reduced 24.55%	98,959 $120,000
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $211,280 - $1.24 Million	101,577 Added 343.34%	131,162 $282,000
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $67,135 - $103,451	5,848 Added 24.64%	29,585 $351,000
Q3 2021 Nov 10, 2021	BUY	$14.57 - $17.72 $345,848 - $420,619	23,737 New	23,737 $368,000

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.